Heather Mayfield

• East High School- Cheyenne Wyoming

• Accountant/Unblinded Pharmacist- Research Integrity, LLC
• Pharmacy Technician- CVS

• IATA: Computer training; Current certificate holder
• GCP CITI: Current certificate holder

• Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Underlying HeFH and/or Atherosclerotic Cardiovascular Disease Who are Not Adequately Controlled by Their Lipid-Modifying Therapies
• A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor Xia Inhibitor, Versus Apixaban in Participants with AF (LIBREXIA-AF)
• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of REL-1017 for Major Depressive Disorder (The RELIANCE-II Study)
• A Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety of REL-1017 as a Treatment of Major Depressive Disorder (RELIANCE-OLS)
• A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Trail to Evaluate the Efficacy and Safety of a Respiratory Syncytial Virus (RSV) Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy
• A Multicenter, Randomized, Active-Controlled Study to Evaluate the Safety and Tolerability of Two Blinded Doses of Abelacimab (MAA868) Compared with Open-Label Rivaroxaban in Patients with AF (AZALEA)
• A multi-center, prospective, open-label, controlled study of the pharmocokinetics and safety of the Licart topical system in pediatric and adult participants with Minor Soft Tissue Injuries. (18US-FHp04)
• A Multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and oler with AF at risk for stroke.
• A multi-center, randomized, double-blind, parallel-group, 20-week dose-finding study to evaluate efficacy, safety, and tolerability of XXB750 in patients with resistant hypertension 
• Obicetrapib and Cardiovascular Outcomes: A Placebo-Contolled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants with Athersclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally tolerated Lipid-Modifying Therapies. (Prevail)
• A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisirin on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT)

Have a question or want to learn more about our work? Get in touch with Research Integrity Research Foundation today. We're always happy to hear from members of the community who share our passion for scientific research.